This announcement is a separate document:
自愿披露关于HP537片用于治疗血液系统恶性肿瘤的临床I/II期试验申请获得美国FDA批准的公告
Announcement of voluntary disclosure of the clinical phase I/II trial application for HP537 for the treatment of hematological malignancies approved by the United States FDA.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.